Published on:

New Jersey Jury Slams C.R. Bard with $68 Million Pelvic Mesh Verdict

This week, a New Jersey jury has handed down another substantial verdict in the most recent pelvic mesh lawsuit. The product liability verdict states C.R. Bard must pay out compensatory damages totaling $33 million and punitive damages totaling $35 million.

The reasoning behind this multi-million dollar verdict was that C.R. Bard overall failed to warn doctors about their mesh product’s potential negative side effects and risks. Accordingly, C.R. Bard’s mesh products were deemed deficient and unsafe.

The plaintiff in this caseMary McGinnis was implanted with the company’s Avaulta Solo Support System and Align Trans-Obturator Urethral Support System in 2009. After undergoing her implant procedure involving the C.R. Bard mesh products she experienced multiple unwanted negative side effects. The unwanted results lead to McGinnis filing a product liability claim against the company in 2011.

The plaintiff’s allegations made at trial stated, among other things, that C.R. Bard knew about the shortcomings of their mesh devices and that they did not warn medical professionals of these problems. Moreover, the plaintiff continued with the claim that if the medical professionals had been aware of the company’s mesh product problems and defects they would not have implanted patients using C.R. Bard’s defective mesh products.

If you or a loved one has experienced negative or unwanted outcomes due to mesh operations or subsequent revision surgery please contact the Naumes Law Group for a free consultation at 844-826-8445 or online at www.naumeslaw.com.